赫赛汀与化疗药物联合应用治疗转移性乳腺癌疗效分析  

The Clinic Effect of Herceptin Combined with Chemotherapy on Metastatic Breast Cancer

作　　者：赵怡[1] 章骏[1] 杨志刚[1] 王群[1] 

机构地区：[1]上海市杨浦区市东医院乳腺外科,200438

出　　处：《实用癌症杂志》2012年第2期171-173,共3页The Practical Journal of Cancer

摘　　要：目的探讨赫赛汀与化疗药物联合应用治疗转移性乳腺癌的临床疗效及安全性。方法对4例人类表皮生长因子受体-2(HER-2)阳性转移性乳腺癌患者给予赫赛汀初始剂量4 mg/kg静脉滴注,之后2 mg/kg,每周1次,连续使用;异长春花碱(NVB)25 mg/m2静脉滴注15 min,第1、5天;顺铂(DDP)70 mg/m2静脉滴注3 h,第1～3天。每4周为1个疗程,至少进行2个疗程,观察患者的疗效及不良反应。结果 4例患者的生存时间为18～30个月,中位生存时间为25个月。治疗2个疗程后,有效率为75.0%,疾病控制率为100.0%;主要毒性为消化道反应及Ⅰ～Ⅱ度白细胞减少,未观察到心脏毒性。结论赫赛汀与NVP等化疗药物联合治疗HER-2阳性转移性乳腺癌具有较好的疗效与安全性,值得临床推广。Objective To explore clinical effect and safety of herceptin combined with chemotherapy on metastatic breast cancer.Methods 4 cases of human epidermal growth factor receptor-2（HER2） over-expressing metastatic breast cancer patients were given treatment as follow： herceptin（4 mg/kg on day 0,followed by 2mg/kg weekly）,vinorelbine（25 mg/m2 on day 1 and day 5 respectively）,cisplatinum（20 mg/m2 on day 1-3） and 5-FU（1.0g on day 1-3）.The treatment was repeated every 4 weeks,and the treatment effect was evaluated after 2 courses of treatment.Results The survival time was 18~30 months,and the median survival time was 25 months.After 2 courses of treatment,the effect rate and disease control rate was 75% and 100%,respectively.The major toxicities were gastrointestinal toxicity and the grade Ⅰ~Ⅱ leucopenia.No cardiac toxicity was observed.Conclusion Chemotherapy combined with Herceptin has good curative effect with acceptable toxicities in the treatment of metastatic breast cancer.

关 键 词：转移性乳腺癌 赫赛汀 化疗 人类表皮生长因子受体-2 

分 类 号：R737.9[医药卫生—肿瘤]